Article Sidebar
Views pdf: 45
RESEARCH ON FACTORS RELATED TO INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS PATIENTS
Main Article Content
Abstract
Introduction: Interstitial lung disease (ILD) is one of the extrapulmonary manifestations of ILD. MUC5B gene mutations have been found to be associated with ILD in ILD patients. In Vietnam, there are very few studies on ILD in ILD and no studies on MUC5B gene mutations in ILD patients. Methods: Prospective study describing all ILD patients with ILD diagnosed, treated and monitored in the Department of Internal Medicine, Rheumatology at Gia Dinh People's Hospital from January 2023 to April 2024. We enrolled 306 patients with RA, of which 101 were diagnosed with ILD by high-resolution chest CVLT according to ATS/ERS/JRS/ALAT 2018 criteria. Results: In the group of RA-ILD, women accounted for 91.1%, the male: female ratio was 1:9, and the group of patients over 50 years old accounted for 87.1%. The duration of RA ≥5 years had a higher rate of ILD than the group with RA <5 years. There was no statistically significant difference between the 2 groups of patients with and without ILD in terms of gender, age, and medical history. Clinically, the group of patients with ILD had the majority of patients with symptoms of dyspnea, accounting for 63.4%. It was noted that patients with ILD had higher respiratory symptoms than patients without ILD with statistical significance. The rate of MUC5B gene rs35705950 mutation in patients RA-ILD is 17 cases, accounting for 5.6%. MUC5B gene mutation is associated with ILD in patients with rheumatoid arthritis with statistical significance. Conclusion: MUC5B gene rs35705950 mutation is associated with ILD in RA patients. It is necessary to screen for ILD in patients with rheumatoid arthritis with the following characteristics: male, >50 years old, with rheumatoid arthritis for 5 years or more.
Article Details
Keywords
Interstitial lung disease, rheumatoid arthritis; MUC5B gene mutation
References
2. Gabbay, E.; Tarala, R.; Will, Ret al (1997), “Interstitial lung disease in recent onset rheumatoid arthritis”. Am. J. Respir. Crit. Care Med. 156, 528–535.
3. Juge P-A, Lee JS, Ebstein E, et al (2018). “MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease.” N Engl J Med ; 379: 2209–2219.
4. Cavagna, L., Monti, S., Grosso, V. et al. (2012). “The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis.” BioMed Research International(1), 759760.
5. Doyle TJ, Patel AS, Hatabu H, et al (2015). “Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers”, Am J Respir Crit Care Med 191: 1403–1412.
6. Juge PA, Solomon JJ, van Moorsel CHM, et al (2021), “MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression”, Semin Arthritis Rheum, 51(5): 996-1004. doi: 10.1016/j.semarthrit.2021.07.002
7. Assayag, D.; Lubin, M.; Lee, J.S.; et al (2014). “Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.” Respirology , 19, 493–500.
8. Klester, E.; Klester, K.; Shoykhet, Y.; et al (2019). “Risk factors of interstitial lung diseases in patients with rheumatoid arthritis.” Eur. Respir. Soc. 54,
9. Aubart, F.; Crestani, B.; Nicaise-Roland, P et al (2011). “High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis.” J. Rheumatol, 38, 979–982.
10. Kelly, C.A.; Saravanan, V.; Nisar, M. et al (2014). “Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics—A large multicentre UK study.” Rheumatology, 53, 1676–1682.